These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16357794)

  • 1. Subcutaneous insulin resistance successfully circumvented on long term by peritoneal insulin delivery from an implantable pump in four diabetic patients.
    Riveline JP; Vantyghem MC; Fermon C; Brunet C; Gautier JF; Renard E; Charpentier G;
    Diabetes Metab; 2005 Nov; 31(5):496-8. PubMed ID: 16357794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extreme subcutaneous insulin resistance: a misunderstood syndrome.
    Soudan B; Girardot C; Fermon C; Verlet E; Pattou F; Vantyghem MC
    Diabetes Metab; 2003 Nov; 29(5):539-46. PubMed ID: 14631332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience.
    Gin H; Renard E; Melki V; Boivin S; Schaepelynck-Bélicar P; Guerci B; Selam JL; Brun JM; Riveline JP; Estour B; Catargi B;
    Diabetes Metab; 2003 Dec; 29(6):602-7. PubMed ID: 14707889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.
    Nathan DM; Dunn FL; Bruch J; McKitrick C; Larkin M; Haggan C; Lavin-Tompkins J; Norman D; Rogers D; Simon D
    Am J Med; 1996 Apr; 100(4):412-7. PubMed ID: 8610727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative estimation of insulin sensitivity in type 1 diabetic subjects wearing a sensor-augmented insulin pump.
    Schiavon M; Dalla Man C; Kudva YC; Basu A; Cobelli C
    Diabetes Care; 2014; 37(5):1216-23. PubMed ID: 24319120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptoms, hormones, and glucose fluxes during a gradual hypoglycaemia induced by intraperitoneal vs venous insulin infusion in Type I diabetes.
    Selam JL; Medlej R; M'bemba J; Chevalier A; Guyon F; Ashworth L; Slama G
    Diabet Med; 1995 Dec; 12(12):1102-9. PubMed ID: 8750221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance.
    Brossard JH; Havrankova J; Rioux D; Bertrand S; D'Amour P
    Diabet Med; 1993 Mar; 10(2):174-6. PubMed ID: 8458196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid").
    Campbell IW; Kritz H; Najemnik C; Hagmueller G; Irsigler K
    Diabetes Res; 1984 Jul; 1(2):83-8. PubMed ID: 6442226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calculating the insulin to carbohydrate ratio using the hyperinsulinaemic-euglycaemic clamp-a novel use for a proven technique.
    Bevier WC; Zisser H; Palerm CC; Finan DA; Seborg DE; Doyle FJ; Wollitzer AO; Jovanovic L
    Diabetes Metab Res Rev; 2007 Sep; 23(6):472-8. PubMed ID: 17315240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insulin substitution: new insulins, new modes of delivery].
    Renard E
    J Soc Biol; 2007; 201(2):141-8. PubMed ID: 17978746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion.
    Rieger C; Kurz K; Mueller-Hoffmann W; Gehr B; Liebl A
    J Diabetes Sci Technol; 2019 Nov; 13(6):1158-1160. PubMed ID: 31195815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients.
    Selam JL; Raccah D; Jean-Didier N; Lozano JL; Waxman K; Charles MA
    Diabetes Care; 1992 Jan; 15(1):53-8. PubMed ID: 1737542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes.
    Haardt MJ; Selam JL; Slama G; Bethoux JP; Dorange C; Mace B; Ramaniche ML; Bruzzo F
    Diabetes Care; 1994 Aug; 17(8):847-51. PubMed ID: 7956629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients.
    Nevalainen P; Lahtela JT; Mustonen J; Pasternack A
    Nephrol Dial Transplant; 1997 Jan; 12(1):145-50. PubMed ID: 9027790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: favourable effects on hypoglycaemic episodes.
    van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Bilo HJ; Kleefstra N
    Diabetes Res Clin Pract; 2014 Nov; 106(2):256-63. PubMed ID: 25305134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of apolipoprotein B100 metabolism between continuous subcutaneous and intraperitoneal insulin therapy in type 1 diabetes.
    Duvillard L; Florentin E; Baillot-Rudoni S; Lalanne-Mistrich ML; Brun-Pacaud A; Petit JM; Brun JM; Gambert P; Vergès B
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5761-4. PubMed ID: 16091481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin.
    Tokuyama Y; Nozaki O; Kanatsuka A
    Diabetes Res Clin Pract; 2001 Dec; 54(3):209-12. PubMed ID: 11689276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
    Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.